RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
PR91509
TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire=KYODO JBN/ --
- COVID-19 and long COVID patients are at increased risk of developing kidney
damage
- Opaganib significantly decreased kidney fibrosis in a preclinical in vivo
model
- Renal fibrosis is a progressive process which occurs in patients with chronic
kidney disease (CKD) and can ultimately lead to end-stage renal failure
- Opaganib is a novel, late clinical-stage oral pill drug candidate with dual
anti-inflammatory and antiviral activity and has already demonstrated strong
inhibition against variants of concern, including Delta
- The global 475-patient Phase 2/3 study with opaganib oral pill in
hospitalized COVID-19 patients has completed treatment and follow up phase,
with top-line results upcoming
RedHill Biopharma Ltd. [ https://www.redhillbio.com/ ](Nasdaq: RDHL)
("RedHill" or the "Company"), a specialty biopharmaceutical company, today
announced results of a new preclinical study demonstrating opaganib's
(ABC294640)[1] efficacy in significantly decreasing renal fibrosis in a
unilateral ureteral obstruction-induced renal interstitial fibrosis model.
Reports suggest that over 20% of hospitalized COVID-19 patients experience
acute renal failure[2].
Kidney fibrosis generally leads to loss of tissue function and subsequent organ
failure, with high mortality rate. New therapeutic small molecules to modulate
fibrosis are urgently needed. The aim of the in vivo efficacy study was to
verify the effect of opaganib on kidney inflammation and fibrosis in a
unilateral ureteral obstruction (UUO) model – a well characterized model for
renal fibrosis. Results from the study showed that opaganib significantly
decreased renal fibrosis.
"A final, common pathway in chronic kidney disease is fibrosis, the formation
of internal scar tissue, which can cause devastating effects and can ultimately
lead to end-stage kidney failure. This new preclinical data, demonstrating
opaganib's ability to decrease kidney fibrosis, along with its observed
anti-inflammatory properties, positions opaganib as a potential novel therapy
for the millions of patients suffering from chronic kidney disease and
potentially extends to COVID-19 patients with Acute Kidney Injury (AKI) who are
at risk of developing renal fibrosis," said Reza Fathi, PhD., RedHill's Senior
VP, R&D. "Kidney injury and its associated progression to fibrosis is an
important facet in both the acute phase of COVID-19 and in long COVID. Recent
research has shown that after acute kidney injury, which we know can be a
result of COVID-19 infection, the kidneys often fail to repair themselves
properly and that sphingosine kinase-2 (SK2), which is inhibited by opaganib,
is part of this process. These findings provide further support for the
extensive work we are doing with opaganib in COVID-19. With the upcoming
readout, we expect to learn more about kidney outcomes from hospitalized
COVID-19 patients treated with opaganib in our global Phase 2/3 study."
Renal fibrosis, a common outcome of chronic kidney disease (CKD), is
characterized by an excessive accumulation and deposition of extracellular
matrix (ECM) components and fibrous tissue. Renal fibrosis may ultimately lead
to end-stage renal failure, a devastating disorder that requires dialysis or
kidney transplantation. CKD is a very common disease, affecting 15% of U.S.
adults[3].
Recent studies have found that patients infected with SARS-CoV-2 are at
increased risk of developing kidney damage, as well as chronic and end-stage
kidney disease., associated with morbidity and mortality in these patients.
Findings have suggested that beyond the acute phase of the disease, COVID-19
survivors, even those who did not require hospitalization, exhibit an increased
risk of developing major adverse kidney disease such as CKD. In addition, data
suggests that approximately 10% of people infected with COVID-19 may experience
long COVID (post-acute sequalae), potentially involving acute kidney-related
outcomes[4].
Opaganib, a leading novel small molecule investigational oral pill in
development for the treatment of COVID-19, is a unique host targeted, dual
antiviral and anti-inflammatory drug that acts on the cause and effect of
COVID-19. It is believed to exert its antiviral effect by selectively
inhibiting SK2, a key enzyme produced in human cells that may be recruited by
the virus to support its replication. Opaganib's global 475-patient Phase 2/3
study in hospitalized patients with COVID-19 has completed its treatment and
follow up phase, and study top-line results are upcoming.
Evaluations of blinded blended intubation and mortality rates from the Phase
2/3 study have been encouraging compared to reported rates of mortality from
large platform studies such as RECOVERY, and other studies in similar patient
populations[5]. Furthermore, the opaganib Phase 2/3 study has also passed four
Data Safety Monitoring Board reviews, as well as a futility review, extending
the total opaganib safety database to more than 460 patients and healthy
subjects. Opaganib previously delivered positive U.S. Phase 2 data in patients
with severe COVID-19, has been recently published in medRxiv [
https://www.medrxiv.org/content/10.1101/2021.08.23.21262464v1 ]. Additionally,
encouraging use of opaganib under compassionate use exemption has been
experienced in Israel and Switzerland.
About Opaganib (ABC294640)
Opaganib, a new chemical entity, is a proprietary, first-in-class,
orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, with dual
anti-inflammatory and antiviral activity. Opaganib is host-targeted and is
expected to be effective against emerging viral variants, having already
demonstrated strong inhibition against variants of concern, including Delta.
Opaganib has also shown anticancer activity and positive preclinical results in
renal fibrosis, and also has the potential to target multiple oncology, viral,
inflammatory, and gastrointestinal indications.
Opaganib is being evaluated as a treatment for COVID-19 pneumonia in a global
Phase 2/3 study that has completed patient treatment and follow-up, with
top-line results upcoming. Opaganib previously delivered positive U.S. Phase 2
data in patients with severe COVID-19, recently published in medRxiv [
https://www.medrxiv.org/content/10.1101/2021.08.23.21262464v1 ].
Opaganib has also received Orphan Drug designation from the U.S. FDA for the
treatment of cholangiocarcinoma and is being evaluated in a Phase 2a study in
advanced cholangiocarcinoma and in a Phase 2 study in prostate cancer. Based on
a preliminary review of partial unaudited data, the ongoing study in prostate
cancer has met its primary endpoint. Patient accrual, treatment and analysis in
this study are ongoing.
Opaganib demonstrated potent antiviral activity against SARS-CoV-2, the virus
that causes COVID-19, inhibiting viral replication in an in vitro model of
human lung bronchial tissue. Additionally, preclinical in vivo studies have
demonstrated opaganib's potential to ameliorate inflammatory lung disorders,
such as pneumonia, and have shown decreased fatality rates from influenza virus
infection and amelioration of Pseudomonas aeruginosa-induced lung injury by
reducing the levels of IL-6 and TNF-alpha in bronchoalveolar lavage fluids[6].
The ongoing clinical studies with opaganib are registered on
www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of
Health, which provides public access to information on publicly and privately
supported clinical studies.
About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company
primarily focused on gastrointestinal and infectious diseases. RedHill promotes
the gastrointestinal drugs, Movantik(R) for opioid-induced constipation in
adults, Talicia(R) for the treatment of Helicobacter pylori (H. pylori)
infection in adults, and Aemcolo(R) for the treatment of travelers' diarrhea in
adults. RedHill's key clinical late-stage development programs include: (i)
RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous
mycobacteria (NTM) disease; (ii) opaganib (ABC294640), a first-in-class oral
SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program
for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma
ongoing; (iii) RHB-107 (upamostat), an oral serine protease inhibitor in a U.S.
Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple
other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with
positive results from a first Phase 3 study for Crohn's disease; (v) RHB-102 ,
with positive results from a Phase 3 study for acute gastroenteritis and
gastritis and positive results from a Phase 2 study for IBS-D; and (vi)
RHB-106, an encapsulated bowel preparation. More information about the Company
is available at www.redhillbio.com / https://twitter.com/RedHillBio.
This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements may be
preceded by the words "intends," "may," "will," "plans," "expects,"
"anticipates," "projects," "predicts," "estimates," "aims," "believes,"
"hopes," "potential" or similar words. Forward-looking statements are based on
certain assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company's control and cannot be
predicted or quantified, and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks
and uncertainties include the risk that in the next studies opaganib will not
be found effective in decreasing renal fibrosis, the delay in top-line data
from the Phase 2/3 COVID-19 study for opaganib, that the Phase 2/3 COVID-19
study for opaganib may not be successful and, even if successful, such study
and results may not be sufficient for regulatory applications, including
emergency use or marketing applications, and that additional COVID-19 studies
for opaganib are likely to be required by regulatory authorities to support
such potential applications and the use or marketing of opaganib for COVID-19
patients, that opaganib will not be effective against emerging viral variants,
as well as risks and uncertainties associated with (i) the initiation, timing,
progress and results of the Company's research, manufacturing, preclinical
studies, clinical trials, and other therapeutic candidate development efforts,
and the timing of the commercial launch of its commercial products and ones it
may acquire or develop in the future; (ii) the Company's ability to advance its
therapeutic candidates into clinical trials or to successfully complete its
preclinical studies or clinical trials (iii) the extent and number and type of
additional studies that the Company may be required to conduct and the
Company's receipt of regulatory approvals for its therapeutic candidates, and
the timing of other regulatory filings, approvals and feedback; (iv) the
manufacturing, clinical development, commercialization, and market acceptance
of the Company's therapeutic candidates and Talicia(R); (v) the Company's
ability to successfully commercialize and promote Movantik(R), Talicia(R) and
Aemcolo(R); (vi) the Company's ability to establish and maintain corporate
collaborations; (vii) the Company's ability to acquire products approved for
marketing in the U.S. that achieve commercial success and build and sustain its
own marketing and commercialization capabilities; (viii) the interpretation of
the properties and characteristics of the Company's therapeutic candidates and
the results obtained with its therapeutic candidates in research, preclinical
studies or clinical trials; (ix) the implementation of the Company's business
model, strategic plans for its business and therapeutic candidates; (x) the
scope of protection the Company is able to establish and maintain for
intellectual property rights covering its therapeutic candidates and commercial
products and its ability to operate its business without infringing the
intellectual property rights of others; (xi) parties from whom the Company
licenses its intellectual property defaulting in their obligations to the
Company; (xii) estimates of the Company's expenses, future revenues, capital
requirements and needs for additional financing; (xiii) the effect of patients
suffering adverse events using investigative drugs under the Company's Expanded
Access Program; and (xiv) competition from other companies and technologies
within the Company's industry. More detailed information about the Company and
the risk factors that may affect the realization of forward-looking statements
is set forth in the Company's filings with the Securities and Exchange
Commission (SEC), including the Company's Annual Report on Form 20-F filed with
the SEC on March 18, 2021. All forward-looking statements included in this
press release are made only as of the date of this press release. The Company
assumes no obligation to update any written or oral forward-looking statement,
whether as a result of new information, future events or otherwise unless
required by law.
Company contact:
Adi Frish
Chief Corporate & Business Development Officer
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com
Media contacts:
U.S.: Bryan Gibbs, Finn Partners
+1 212 529 2236
bryan.gibbs@finnpartners.com
UK: Amber Fennell, Consilium
+44 (0) 7739 658 783
fennell@consilium-comms.com
[1] Opaganib is an investigational new drug, not available for commercial
distribution.
[2] Nadim, M.K., Forni, L.G., Mehta, R.L. et al. COVID-19-associated acute
kidney injury: consensus report of the 25th Acute Disease Quality Initiative
(ADQI) Workgroup. Nat Rev Nephrol 16, 747–764 (2020).
[3] Centers for Disease Control and Prevention – Chronic Kidney Disease in the
United States, 2021
[4] Bowe B, Xie Y, Xu E, Al-Aly Z, Kidney Outcomes in Long COVID. JASN Sep 2021
[5] Based on preliminary blinded blended data from 463 patients. The Company
did not conduct a head-to-head comparison study in the same patient population.
The theoretical comparison between the global Phase 2/3 study with opaganib and
reported rates of mortality from large platform studies such as RECOVERY, and
other studies in similar patient populations, serves as a general benchmark and
should not be construed as a direct and/or applicable comparison as if the
Company conducted a head-to-head comparison study.
[6] Xia C. et al. Transient inhibition of sphingosine kinases confers
protection to influenza A virus infected mice. Antiviral Res. 2018 Oct;
158:171-177. Ebenezer DL et al. Pseudomonas aeruginosa stimulates nuclear
sphingosine-1-phosphate generation and epigenetic regulation of lung
inflammatory injury. Thorax. 2019 Jun;74(6):579-591.
Logo - https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg
Source: RedHill Biopharma Ltd.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。